- Definition and classification of mild traumatic brain injury
- Current clinical diagnostic criteria
- Advances in imaging and neurophysiological tools
- Role of biomarkers in diagnosis
- Considerations for differential diagnosis
Mild traumatic brain injury (mTBI) is a prevalent yet often under-recognised condition resulting from an external mechanical force to the head, leading to a transient disturbance of brain function. Commonly associated with sports injuries, falls, and motor vehicle accidents, mTBI accounts for the vast majority of traumatic brain injuries seen in emergency settings. Despite being labelled “mild”, the injury can have significant short- and long-term cognitive, emotional, and physical consequences, underscoring the importance of accurate definition and consistent classification in clinical and research settings.
The definition of mTBI has evolved over recent decades, with multiple professional bodies contributing to consensus-based diagnostic criteria. Central to most definitions is the presence of an alteration in brain function marked by symptoms such as confusion, disorientation, loss of memory for events immediately before or after the trauma (post-traumatic amnesia), brief loss of consciousness (usually less than 30 minutes), and the presence of neurological abnormalities that rapidly resolve. The Glasgow Coma Scale (GCS) score is frequently used to classify the severity of brain injuries, with a score of 13–15 at initial assessment typically indicative of mTBI.
Differentiating mTBI from more severe forms of brain trauma requires careful assessment of consciousness level, duration of post-traumatic amnesia, and imaging findings, when available. Importantly, the classification of mTBI may vary slightly depending on the guidelines adopted; for instance, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the American Congress of Rehabilitation Medicine (ACRM) have all issued criteria that clinicians may refer to. These criteria share common elements, but differ in emphasis—for example, the ACRM includes a broader range of symptoms affecting mental state and cognitive function, while the WHO criteria include biomechanical evidence of head trauma.
Increasing recognition of the heterogeneity of mTBI presentations has led to a push towards more nuanced subcategorisation based not only on the severity of neurological disturbance but also on clinical symptom patterns and recovery trajectory. Some emerging classifications attempt to factor in mechanisms of injury, age, and pre-existing conditions to inform prognosis and rehabilitation strategies. A standardised approach remains critical for research comparisons and for the development of therapeutic trials aimed at improving outcomes in affected individuals.
As such, the refinement of mTBI classification continues to be guided by clinical observations, neurocognitive assessments, and advancements in diagnostic tools, all of which contribute to the ongoing efforts to improve care and outcomes for individuals suffering from this often underestimated condition.
Current clinical diagnostic criteria
Clinical assessment of mild traumatic brain injury typically begins with a thorough evaluation of the patient’s history of injury and presenting symptoms. The contemporary diagnostic criteria incorporate both objective signs and subjective symptomatology to enhance early detection and exclude other causes of neurological disturbance. Clinicians frequently rely on tools such as the Glasgow Coma Scale (GCS), where a score between 13 and 15 within 30 minutes post-injury supports a diagnosis of mTBI. Additional criteria include loss of consciousness lasting no more than 30 minutes, post-traumatic amnesia not exceeding 24 hours, and any alteration in mental state at the time of the accident, such as confusion, disorientation or slowed thought processing.
An important component of the current diagnostic approach is the use of standardised assessment instruments, such as the Rivermead Post-Concussion Symptoms Questionnaire or the Standardised Assessment of Concussion (SAC), to evaluate the cognitive, physical and emotional symptoms commonly associated with mild traumatic brain injury. These tools allow clinicians to document symptom severity and track changes over time, providing crucial information for determining whether further investigation—such as neuroimaging or specialist referral—is warranted.
The diagnostic criteria for mTBI have been refined by a range of professional societies to improve both clinical utility and study comparability. For example, the Centres for Disease Control and Prevention (CDC) has delineated operational definitions that include parameters such as observed or self-reported signs including dazed expressions, balance difficulties, or processing delays. Similarly, the American Congress of Rehabilitation Medicine (ACRM) emphasises the involvement of neurocognitive and neuropsychiatric symptoms, including irritability, slowed reaction times, and sleep disturbances, provided they are temporally related to head trauma and not attributable to other factors such as medication or mental health conditions.
One challenge in the diagnostic process is patient underreporting, either due to lack of awareness of symptom relevance or delayed onset of impairment. As such, repeated follow-up assessments are often essential. Furthermore, clinicians must be alert to atypical presentations and subtle manifestations of injury, especially in populations such as older adults and children, who may not exhibit classic signs of mTBI or may have limited ability to articulate their experiences.
Current clinical practice also recognises that symptom resolution time varies widely, and persistent symptoms beyond the typical recovery window—usually a few weeks—may indicate post-concussion syndrome or uncover underlying psychological conditions. Therefore, refined diagnostic criteria increasingly emphasise a multidimensional assessment model, integrating neurological, cognitive, and psychosocial domains. This holistic approach is vital for ensuring accurate identification and management of mTBI and for guiding appropriate interventions to minimise long-term sequelae.
Advances in imaging and neurophysiological tools
Recent developments in imaging and neurophysiological tools have significantly enhanced the assessment of mild traumatic brain injury, offering clinicians new avenues to support diagnostic criteria and better understand the underlying pathophysiological changes. While conventional neuroimaging techniques such as computed tomography (CT) and standard magnetic resonance imaging (MRI) are still commonly employed in acute settings to rule out more severe intracranial pathology, their sensitivity to the subtle neuronal and axonal damage characteristic of mTBI remains limited. Consequently, attention has shifted towards advanced modalities that provide higher resolution imaging and functional assessment capacities.
Diffusion tensor imaging (DTI), a specific form of MRI that maps the diffusion of water molecules along white matter tracts, has shown promise in detecting microstructural alterations indicative of axonal injury, which may not be visible on standard MRI scans. Studies have demonstrated correlations between DTI changes and clinical symptoms such as attention deficits and memory impairment, suggesting its potential role in subacute and chronic evaluation of mTBI. Similarly, susceptibility-weighted imaging (SWI) can assist in identifying microhaemorrhages or diffuse axonal injury, which may offer a more objective corroboration of clinical symptoms.
Functional MRI (fMRI), which measures brain activity by detecting changes in blood oxygenation, has been instrumental in research settings for elucidating the impact of mTBI on neural circuitry. Resting-state fMRI, in particular, has revealed disruptions in network connectivity within the default mode network and other functional systems, even when structural imaging appears normal. These disturbances correlate with neurocognitive deficits and may provide insights into the persistent symptoms seen in some individuals post-injury. However, due to its complexity and cost, fMRI has not yet become routine in clinical assessment protocols.
In the realm of neurophysiological testing, quantitative electroencephalography (qEEG) has emerged as a non-invasive method to capture real-time brain electrical activity. Alterations in spectral power and coherence observed in mTBI patients suggest cortical dysfunction and have been associated with cognitive impairments. Event-related potentials (ERPs), specifically P300 latency and amplitude, are also being explored as objective markers to complement traditional diagnostic criteria. These methods hold particular promise in early detection, especially in cases where patients downplay symptoms or present with delayed onset of complaints.
Additionally, magnetoencephalography (MEG) is gaining traction for its sensitivity in detecting disruptions in cerebral oscillatory patterns. Though currently limited to specialised centres, MEG has demonstrated a capacity to identify abnormalities in neuronal synchronisation that align with symptom severity and duration. Its potential role in refining the assessment of post-concussion syndrome and tracking recovery trajectories further underscores its diagnostic value.
Despite these advances, limitations remain in terms of standardisation, accessibility, and interpretation of findings across different modalities. Not all imaging or neurophysiological abnormalities are specific to mTBI, and findings must be contextualised within a comprehensive clinical framework. Future integration of these tools into diagnostic criteria may enhance the sensitivity and specificity of mTBI diagnosis, providing a more robust basis for initiating personalised treatment and rehabilitation strategies. Continued research and technological refinement will be crucial to translate these innovations into routine clinical practice and ensure they augment, rather than complicate, the assessment and management of patients with mild traumatic brain injury.
Role of biomarkers in diagnosis
In recent years, the pursuit of objective, measurable indicators has led researchers and clinicians to explore biomarkers as a means of enhancing the assessment and diagnostic criteria for mild traumatic brain injury (mTBI). Biomarkers, defined as biological molecules that signal a particular physiological or pathological process, offer promising potential in addressing the limitations of subjective symptom reporting and traditional imaging modalities, particularly in cases where clinical presentation is ambiguous or when patients minimise their symptoms.
Protein biomarkers found in blood, such as glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and neurofilament light chain (NfL), have demonstrated utility in identifying neuronal and glial injury associated with mTBI. For instance, GFAP and UCH-L1 have received regulatory approval in certain countries for use as adjunctive tools in the early evaluation of suspected mTBI. Clinical studies show that elevated levels of GFAP and UCH-L1, when measured within 12 hours of injury, can correlate with intracranial lesions seen on CT scans and can aid in determining the necessity for imaging in emergency settings.
Further research into S100B, a calcium-binding protein predominantly expressed in astrocytes, has shown that its concentrations typically rise after head trauma and may help exclude serious brain injury when levels remain low. However, variability in assay techniques and physiological fluctuations due to extracranial injuries have hindered its widespread adoption into clinical practice. Similarly, the use of tau protein and NfL as markers of axonal injury is an area of intense investigation, particularly in the context of sports-related concussion, where repeat mTBI events may go undetected by conventional means.
Biomarkers also hold potential in informing prognosis and monitoring recovery. Persistently elevated levels of neurodegenerative markers weeks after an mTBI event may signal ongoing pathological changes or risk for prolonged symptoms, such as in post-concussion syndrome. Longitudinal assessment using serial biomarker evaluations could therefore augment current diagnostic criteria by establishing a biological timeline of injury and healing response, offering a more precise stratification of patients for rehabilitation planning.
Salivary, cerebrospinal fluid (CSF), and even ocular biomarkers are being explored as non-invasive or minimally invasive alternatives to blood testing. For example, salivary microRNAs have shown early promise as rapid indicators of central nervous system injury, offering a feasible point-of-care testing option, particularly in field or military settings. Though still under investigation, the development and validation of such platforms could revolutionise the practical application of biomarkers in real-time mTBI assessment scenarios.
Despite these advancements, widespread clinical integration of biomarkers into routine diagnostic workflows remains limited. Challenges include the need for standardisation of assay procedures, establishment of normative reference ranges across demographics, and proof of clinical utility across diverse populations. Furthermore, integrating laboratory results into current diagnostic criteria necessitates a multidisciplinary approach that balances clinical examination with biochemical evidence.
As the understanding of mTBI pathophysiology deepens, the role of biomarkers is expected to expand, providing much-needed objective data to complement clinical and imaging assessments. This integration has the potential to not only improve the accuracy of initial diagnosis but also personalise treatment pathways, reduce unnecessary imaging, and improve long-term outcomes for individuals affected by mild traumatic brain injury.
Considerations for differential diagnosis
Distinguishing mild traumatic brain injury (mTBI) from other medical or psychological conditions that can present with overlapping symptoms is a critical aspect of accurate assessment and a central consideration in refining diagnostic criteria. Given the often non-specific constellation of cognitive, emotional and physical symptoms following a mild head injury—such as fatigue, headaches, mood changes, and concentration difficulties—clinicians are frequently challenged to differentiate mTBI from both physiological effects of trauma and unrelated, co-existing disorders.
One common diagnostic dilemma lies in distinguishing mTBI from psychological conditions that may produce similar symptom profiles, particularly in the absence of visible injury on neuroimaging. Depression, anxiety disorders, post-traumatic stress disorder (PTSD), and somatic symptom disorders can all produce fatigue, irritability, sleep disturbances and cognitive complaints. Such overlap is especially pronounced when emotional distress or psychological trauma has occurred in tandem with a head injury event. In these instances, the clinician must perform a thorough neuropsychiatric assessment to identify whether the reported symptoms stem primarily from direct neurological insult or reflect a psychological response to the injury or broader context.
Furthermore, functional neurological symptom disorders (FNSD), historically referred to as conversion disorders, can mimic several symptoms associated with mTBI, including dizziness, vision loss and motor disturbances, in the complete absence of neuropathological correlates. While the co-existence of FNSD and mTBI is well-documented, diagnosing them accurately requires an integrated approach that includes neurologic evaluation, psychiatric consultation, and, in some cases, advanced physiological testing to explore inconsistencies or paradoxical symptom patterns.
Medical conditions unrelated to head injury should also be considered in the differential diagnosis. For example, sleep disorders such as obstructive sleep apnoea and insomnia can present with cognitive slowing, mood changes and fatigue—all symptoms also attributed to mTBI. Similarly, endocrine anomalies, notably hypopituitarism following traumatic injury, can create a milieu of symptoms that may be mistakenly ascribed solely to brain trauma unless biochemical screening is conducted.
In elderly populations, the assessment becomes even more complex due to the high prevalence of age-associated cognitive decline, comorbidities, and polypharmacy. Conditions such as early-stage dementia, medication side effects, or metabolic disturbances—particularly involving glucose, sodium or thyroid levels—may present with neurobehavioural symptoms indistinguishable from mTBI. Therefore, comprehensive geriatric evaluation and a detailed medication review are essential to avoid misattribution of symptoms.
Additionally, the timing and evolution of symptoms play a central role in the diagnostic process. For instance, acute presentation of memory loss or confusion shortly after a traumatic event is more suggestive of mTBI, whereas gradual onset cognitive impairment in the weeks or months that follow may raise concerns about neurodegenerative conditions like Alzheimer’s disease or chronic traumatic encephalopathy (CTE) in individuals with repeated head trauma exposure. The latter, although still an evolving diagnostic entity, must be considered in athletes, military personnel and others with high cumulative exposure to brain trauma.
Sensory and vestibular conditions, such as benign paroxysmal positional vertigo (BPPV) or peripheral vestibular disorders, are another potential source of diagnostic confusion. Symptoms of dizziness and balance instability are common in mTBI but may also indicate inner ear dysfunction or vestibular migraine. Therefore, audiologic and vestibular assessments may be warranted in patients presenting with prominent balance complaints, especially when these symptoms are prolonged or do not follow the typical recovery trajectory of mTBI.
To navigate these overlapping clinical pictures, a structured diagnostic process that incorporates a detailed patient history, temporal symptom analysis, physical and neurological examination, and targeted diagnostic testing is essential. Standardised symptom inventories and neuropsychological assessments can aid in quantifying deficits and tracking symptom progression, while advanced imaging and biomarker testing may offer further clarity in ambiguous cases.
Ultimately, a multimodal approach to differential diagnosis helps prevent both over-diagnosis and under-diagnosis of mild traumatic brain injury, supports the development of tailored management strategies, and enhances the reliability of diagnostic criteria. The integration of such an approach into routine clinical practice ensures that patients receive appropriate care based not only on symptomatology but also on a deep understanding of potential alternative or co-occurring conditions.
